Table 1.
Indications for DOACs.
| Indications | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
|---|---|---|---|---|
| Prevention | ||||
| Stroke and systemic embolism in patients with NVAF | Yes | Yes | Yes | Yes |
| Recurrence of DVT and PE in patients who have been previously treated | Yes | Yes | ||
| DVT and PE in patients who have undergone hip/knee replacement surgery | Yes | Yes | Yes | |
| Recurrence DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months | Yes | |||
| Major cardiovascular events (CV death, MI and stroke) in patients with chronic CAD or PAD | Yes (in combination with aspirin) | |||
| Treatment | ||||
| DVT and PE in patients who have been treated with a parenteral anticoagulant for 5–10 days | Yes | Yes | Yes |
CAD: coronary artery disease; CV: cardiovascular; DVT: deep venous thrombosis; MI: myocardial infarction; NVAF: non-valvular atrial fibrillation; PAD: peripheral artery disease; PE: pulmonary embolism.